Martin Schear, MD
Family Medicine · Dayton, OHNPI 1801885355
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $17,889 of the $28,304 with a category attached, or 63.2%. It is spread thinly across 58 manufacturers, the largest accounting for just 21.5%. Reporting peaked in 2019 at $9,126 and has fallen 80.2% since, to $1,809 in 2025. Among family medicine clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,159 payments — averaging $24.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$6K
- Life Technologies Corporation$4K
- AstraZeneca$4K
- GSK$3K
- AbbVie$2K
- Merck$1K
- plus $8K from 52 others
Across 541 payments — averaging $4026.10 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$1.3M
- Seqirus USA Inc$311K
- Merck$152K
- Novo Nordisk AS$119K
- GSK$118K
- AstraZeneca$83K
- plus $136K from 12 others
What the payments were for
- Speaking & faculty fees$4,25015%
- Travel & lodging$6,10622%
- Food & beverage$17,88963%
- Education$390%
- Gifts$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$28,304 in reported general payments places this provider in the 95th percentile of 3,983 family medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 163 | $119,548 |
| EliquisApixaban | 157 | $106,199 |
| FarxigaDapagliflozin Propanediol | 157 | $101,894 |
| OzempicSemaglutide | 69 | $78,510 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 96 | $65,029 |
| TrulicityDulaglutide | 45 | $57,232 |
| JardianceEmpagliflozin | 79 | $54,470 |
| RybelsusSemaglutide | 30 | $38,662 |
| SymbicortBudesonide/Formoterol Fumarate | 143 | $34,985 |
| MounjaroTirzepatide | 29 | $30,510 |
| Breo ElliptaFluticasone/Vilanterol | 65 | $25,529 |
| EntrestoSacubitril/Valsartan | 30 | $23,976 |
| MyrbetriqMirabegron | 41 | $22,175 |
| XareltoRivaroxaban | 28 | $21,381 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 843 | $19,084 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort, Lokelma, Airsupra | $4,114 | $224,947436 claims |
| MerckJanuvia, Dulera | $1,474 | $127,844187 claims |
| PfizerEliquis, Nurtec Odt | $6,076 | $125,102171 claims |
| Novo NordiskOzempic, Rybelsus | $678 | $117,17399 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $193 | $87,74274 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Stiolto Respimat | $337 | $75,845116 claims |
| GSKBreo Ellipta, Trelegy Ellipta | $2,547 | $43,48393 claims |
| NovartisEntresto | $258 | $23,97630 claims |
| Astellas Pharma US IncMyrbetriq | $404 | $22,17541 claims |
| Johnson & JohnsonXarelto | $101 | $21,38128 claims |
| BayerKerendia | $566 | $13,26921 claims |
| Hikma Pharmaceuticals USAMitigare | $25 | $5,55912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,983 family medicine providers in Ohio.
Other family medicine in Dayton
- Kimbra JoyceDayton$20K
- Kwabena OtengSpringdale$2M
- Brian BeesleyColumbus$1.4M
- Darshana PatelBeachwood$648K
- Thomas GraceFindlay$503K
- Susan RatayAshtabula$379K
- Shannon TrotterSpringfield$348K
- Michael HeileCincinnati$272K
- Bradley EverlyMaumee$266K
- Tricia BedrickCuyahoga Falls$259K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.